Recruiting
Phase 1
Phase 2

VRN110755

Sponsor:

Voronoi, Inc

Code:

NCT07699328

Conditions

EGFR-Mutant Non-Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

VRN110755

Study Details

Brief summary:

This first-in-human, Phase 1/2, multicenter, open-label, non-randomized study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of VRN110755, a highly selective oral epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR-mutant non-small cell lung cancer (NSCLC).

The study includes a Phase 1a dose-escalation portion, a Phase 1b dose-expansion portion, and a Phase 2 evaluation. The study is designed to determine the maximum tolerated dose and recommended Phase 2 dose of VRN110755 and to evaluate preliminary and confirmatory antitumor activity in patients with EGFR-mutant NSCLC, including patients with acquired resistance following EGFR tyrosine kinase inhibitor therapy.

Conditions

EGFR-Mutant Non-Small Cell Lung Cancer

Study ID

NCT07699328

Start date

Mar 26, 2024

Status verified date

Jul, 2026

Completion date

Jan 1, 2029

Anticipated

Primary completion date

Jan 1, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adults aged 18 years or older (19 years or older in the Republic of Korea).
  • Able to understand, sign, and provide written informed consent.
  • Histologically or cytologically confirmed advanced, metastatic, or recurrent predominantly nonsquamous non-small cell lung cancer (NSCLC) with a documented epidermal growth factor receptor (EGFR) mutation.
  • At least one measurable extracranial lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
  • Documented EGFR mutation determined by tumor tissue or liquid biopsy.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Able to swallow oral capsules and comply with study procedures.
  • Women of childbearing potential must have a negative pregnancy test, must not be breastfeeding, and must agree to use effective contraception during the study and for 7 months after the last safety follow-up visit. Men must agree to use effective contraception during the study and for 6 months after the last safety follow-up visit.
  • No appropriate standard treatment options are available or standard treatment is not considered feasible, in the opinion of the investigator.
  • Participants must meet the disease-specific eligibility criteria for one of the following study groups:

  • Phase 1a

  • NSCLC with EGFR activating, resistant, uncommon, or complex mutations, including but not limited to exon 19 deletion (Del19), L858R, C797S, or other uncommon EGFR mutations.
  • Radiographic disease progression following at least 2 cycles of prior EGFR tyrosine kinase inhibitor (TKI) therapy or discontinuation of prior EGFR TKI therapy because of toxicity, with no remaining standard therapy expected to provide clinical benefit.
  • Phase 1b - Cohort A

  • NSCLC with EGFR exon 19 deletion or L858R mutation plus a C797X resistance mutation following disease progression after first-line treatment with a third-generation EGFR TKI (including osimertinib, lazertinib, or aumolertinib).
  • Phase 1b - Cohort B

  • Treatment-naïve NSCLC with common EGFR mutations.
  • Phase 1b - Cohort C

  • NSCLC with atypical or uncommon EGFR mutations (including G719X, L861Q, S768I, E709X, R776H, L747S, or combinations of these mutations) previously treated with at least one systemic therapy, including an EGFR TKI, with no remaining standard therapy expected to provide clinical benefit.
  • Phase 1b - Cohort D

  • Treatment-naïve NSCLC with atypical EGFR mutations.

Exclusion Criteria:

  • Received an investigational anticancer therapy within 14 days or 5 half-lives (whichever is longer) before the first dose of study treatment.
  • Unresolved side effects from previous anticancer therapy greater than Grade 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), except for Grade 2 peripheral neuropathy or alopecia.
  • Pregnant or breastfeeding, or planning to become pregnant during the study.
  • NSCLC with an EGFR or HER2 exon 20 insertion mutation.
  • Another active malignancy within the past 3 years, with the exception of adequately treated cancers considered cured.
  • Inadequate bone marrow, kidney, or liver function based on protocol-defined laboratory criteria.
  • Active infection requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days before the first dose of study treatment.
  • Active hepatitis B or hepatitis C infection, or known human immunodeficiency virus (HIV) infection.
  • Receipt of a live vaccine within 4 weeks before the first dose of study treatment.
  • Use of strong or moderate cytochrome P450 (CYP) 3A inhibitors or inducers, certain herbal supplements, or other prohibited medications within the protocol-defined washout period.
  • Major surgery within 4 weeks before the first dose of study treatment or incomplete recovery from major surgery.
  • Receipt of prior anticancer therapy within the protocol-defined washout period, including systemic therapy, immunotherapy, or radiotherapy.
  • Symptomatic or uncontrolled central nervous system (CNS) metastases or spinal cord compression requiring increasing doses of corticosteroids. Participants with treated and stable CNS metastases or asymptomatic CNS disease may be eligible.
  • Requirement for systemic corticosteroid therapy exceeding the protocol-defined limit.
  • Clinically significant cardiovascular disease, including prolonged QT interval, clinically significant arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, uncontrolled hypertension, reduced left ventricular ejection fraction, or use of medications known to prolong the QT interval.
  • History of interstitial lung disease, noninfectious pneumonitis requiring steroid treatment, or current interstitial lung disease or pneumonitis.
  • Inability to swallow oral capsules or gastrointestinal disorders that may interfere with absorption of study treatment.
  • Known allergy or hypersensitivity to VRN110755 or any of its components.
  • Alcohol or drug abuse within the previous 2 years or any medical, psychological, or social condition that, in the opinion of the investigator, would interfere with study participation or interpretation of study results.
  • Use of proton pump inhibitors, histamine-2 receptor antagonists, or locally acting antacids within the protocol-defined washout period or inability to comply with protocol requirements for acid-reducing medications.
  • For Phase 1b and Phase 2 only: Presence of another targetable oncogenic driver alteration with an approved targeted therapy, including MET or HER2 amplification; ALK, ROS1, NTRK, or RET fusion; or BRAF V600E or KRAS G12X mutation.

Study Design

Enrollment

315 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Phase 1a Dose Escalation

Participants with advanced, metastatic, or recurrent EGFR-mutant non-small cell lung cancer (NSCLC) who have experienced disease progression following prior EGFR tyrosine kinase inhibitor (TKI) therapy and harbor activating, resistant, uncommon, or complex EGFR mutations. Participants receive escalating dose levels of VRN110755 to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity and to determine the maximum tolerated dose (MTD).

experimental: Phase 1b Cohort A

Participants with EGFR-mutant NSCLC harboring exon 19 deletion or exon 21 L858R mutations and a C797X resistance mutation following progression on first-line third-generation EGFR TKI therapy, including osimertinib, lazertinib, or aumolertinib. Participants receive VRN110755 to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity and to support selection of the recommended Phase 2 dose.

experimental: Phase 1b Cohort B

Treatment-naïve participants with NSCLC harboring common EGFR mutations. Participants receive VRN110755 to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity in patients who have not previously received systemic treatment for EGFR-mutant NSCLC.

experimental: Phase 1b Cohort C

Participants with NSCLC harboring atypical or uncommon EGFR mutations, including G719X, L861Q, S768I, E709X, R776H, L747S, or combinations thereof, who have previously received at least one prior systemic therapy, including an EGFR TKI, and have no remaining standard treatment options expected to provide clinical benefit. Participants receive VRN110755 to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity.

experimental: Phase 1b Cohort D

Treatment-naïve participants with NSCLC harboring atypical EGFR mutations. Participants receive VRN110755 to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity in patients who have not previously received systemic treatment for EGFR-mutant NSCLC.

Interventions

VRN110755

VRN110755 is an investigational highly selective oral EGFR inhibitor supplied as capsules for oral administration. The drug is designed to target activating EGFR mutations and selected resistance mutations, including C797S, in patients with EGFR-mutant NSCLC.

Primary outcome measure

  • Estimate of Maximum Tolerated Dose (MTD) of VRN110755 [ Time Frame: 28 days ]
  • Number of participants with dose-limiting toxicities (DLTs) following treatment with VRN110755 [ Time Frame: 28 days ]
  • Number of participants experiencing treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events leading to discontinuation [ Time Frame: From first dose until end of study (up to approximately 6 years) ]
  • Number of participants with changes in vital signs from baseline following treatment with VRN110755 [ Time Frame: From baseline through End of Treatment (up to approximately 6 years) ]
  • Number of participants with changes in laboratory test results from baseline following treatment with VRN110755 [ Time Frame: From baseline through End of Treatment (up to approximately 6 years) ]
  • Number of participants with changes in physical examination findings from baseline following treatment with VRN110755 [ Time Frame: From baseline through End of Treatment (up to approximately 6 years) ]
  • Number of participants with changes in ophthalmologic examination findings from baseline following treatment with VRN110755 [ Time Frame: From baseline through End of Treatment (up to approximately 6 years) ]
  • Number of participants with changes in electrocardiogram (ECG) parameters from baseline following treatment with VRN110755 [ Time Frame: From baseline through End of Treatment (up to approximately 6 years) ]
  • Number of participants with changes in Eastern Cooperative Oncology Group (ECOG) Performance Status from baseline following treatment with VRN110755 [ Time Frame: From baseline through End of Treatment (up to approximately 6 years) ]

Central Contacts and Locations

Central contacts

Somi Lee

00 82 32 219 7849somi@voronoi.io

Locations

Princess Margaret Cancer Centre

Recruiting

Toronto, Ontario, Canada, M5G 2M9

Principal Investigator:

Natasha Leighl

More Information

Sponsor

Voronoi, Inc

Last update posted

Jul 13, 2026

Last verified

Jul, 2026

Keywords

  • NSCLC
  • EGFR
  • Epidermal Growth Factor Receptor
  • Non-Small Cell Lung Cancer
  • EGFR Mutation
  • C797S
  • EGFR Tyrosine Kinase Inhibitor Resistance

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Voronoi, Inc on 2026-07-13.